UNASSIGNED: @entity2132 ( @entity2132 ) is the major treatment-related complication after @entity8 ( @entity8 ) from unrelated-donors. Several @entity2132 prophylaxis regimens have been explored, but no regimen has shown superiority. We analyzed transplantation outcomes in 472 consecutive unrelated-donor @entity8 recipients, using @entity205 / @entity1499 (MTX, n  =  314) or @entity205 / @entity618 (MMF, n  =  158) for @entity2132 prophylaxis. Neutrophil engraftment was faster after MMF, days 11 and 14, respectively (P  =  .001). Acute @entity2132 grade II-IV and III-IV occurred in 47% and 28% after MMF compared to 27% and 12% after MTX, respectively (P  <  .001). Nonrelapse mortality (NRM) was 44% and 24%, respectively (P  <  .001). Death associated with @entity2132 occurred in 25% and 8% (P  <  .0001), while other NRM causes occurred in 19% and 16%, respectively (P  =  .39). Relapse mortality was similar. Overall survival was better after MTX, 40% and 29%, respectively (P  =  .006). However, this difference had only borderline significance when adjusting for differences in @entity1 characteristics (HR, 1.3, P  =  .08). To minimize potential selection bias we analyzed outcomes on the basis of an intention-to-treat like analysis. During the years 2008-2009, the leading @entity2132 prophylaxis regimen for unrelated-donor @entity8 included MMF (89% of transplants). During the other periods, MTX was used predominantly (82% of transplants). The two periods were otherwise well-matched. Acute @entity2132 occurred more often in 2008-2009. Death associated with @entity2132 occurred more often, while other NRM causes occurred less often resulting in similar NRM and overall survival. In conclusion, @entity205 /MMF is associated with faster engraftment and possibly with less organ @entity137 than @entity205 /MTX. However, it is associated with increased rates of acute @entity2132 and @entity2132 -associated @entity204 .

The combination of @entity205 and @entity618 is less effective than @entity205 and XXXX in the prevention of acute graft-versus host disease after @entity8 from unrelated donors.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['stem-cell transplantation', 'SCT'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'Acute graft-versus-host disease'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate-mofetil'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']
